Meta-Analyses Link Rosiglitazone to Increased Cardiovascular Risk

THURSDAY, Feb. 6, 2020 -- Rosiglitazone seems to be associated with an increased cardiovascular risk, particularly heart failure, according to data from a systematic review and meta-analyses published online Feb. 5 in The BMJ. Joshua D. Wallach,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news